Tenofovir disoproxil for the treatment of chronic hepatitis B

  • Technology appraisal guidance
  • TA173
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Southampton Health Technology Assessments Centre::

  • Jones J, Colquitt J, Shepherd J, et al, Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B, January 2009.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor

  • Gilead Sciences (tenofovir disoproxil fumarate)

II) Professional/specialist and patient/carer groups:

  • Association of Clinical Microbiologists

  • Association of Medical Microbiologists

  • Association of Nurses in Substance Abuse

  • British Association for Sexual Health and HIV

  • British Association for the Study of the Liver

  • British Infection Society

  • British Transplantation Society

  • Chinese National Healthy Living Centre

  • Health Protection Agency

  • Hepatitis B Foundation UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • South Asian Health Foundation

Other consultees

  • Department of Health

  • Liverpool Primary Care Trust

  • Welsh Assembly Government

III) Commentator organisations (did not provide written evidence and without the right of appeal):

  • Bristol Myers Squibb (entecavir)

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • GlaxoSmithKline (lamivudine)

  • MRC Clinical Trials Unit

  • National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)

  • NHS Quality Improvement Scotland

  • Roche Products (interferon alfa 2a and peginterferon alfa 2a)

  • Southampton Health Technology Assessment Centre, University of Southampton

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on tenofovir disoproxil by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Geoffrey Dusheiko, nominated by Royal College of Physicians – clinical specialist

  • Dr Mark Nelson, nominated by Royal College of Physicians – clinical specialist

  • Mr Anil Patel, nominated by the Hepatitis B Foundation UK – patient expert

  • Ms Stella Pendleton, nominated by the Hepatitis B Foundation UK – patient expert

  • National Institute for Health and Care Excellence (NICE)